Hizal, M. Et Al. 2022. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6 , 1501-1508.

Hizal, M., Bilgin, B., Paksoy, N., Acikgoz, O., Sezer, A., Gurbuz, M., ... Ak, N.(2022). The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6, 1501-1508.

Hizal, Mutlu Et Al. "The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6, 1501-1508, 2022

Hizal, Mutlu Et Al. "The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6, pp.1501-1508, 2022

Hizal, M. Et Al. (2022) . "The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6, pp.1501-1508.

@article{article, author={Mutlu Hizal Et Al. }, title={The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2022, pages={1501-1508} }